Contusugene ladenovec within its licensed indication for the treatment of unresectable recurrent and/or refractory squamous cell carcinoma of the head and neck
Status Suspended
Process STA pre-2018
Referral date 01 March 2009
Topic area
  • Cancer

Cancer reform strategy Batch 3

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: Jeremy Powell
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
14 August 2009 Appraisal suspended

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance